Buspirone for Anxiety After an Accident: What PI Patients Need to Know

James Wong — Founder & Pharmacist, LienScripts | February 9, 2026 | 7 min read

Buspirone (BuSpar) is a non-benzodiazepine anxiolytic commonly prescribed to personal injury patients who develop generalized anxiety disorder following a traumatic accident. Unlike benzodiazepines, it carries no addiction potential, causes no sedation, and can be taken continuously for the duration of a case — all covered under a pharmacy lien at no upfront cost to the patient.

Anxiety After an Accident Is a Medical Diagnosis

Surviving a serious accident — a car crash, a fall, a workplace incident — does not end when the physical injuries are treated. For a significant portion of personal injury patients, the psychological aftermath of trauma manifests as clinically diagnosable generalized anxiety disorder (GAD), post-traumatic stress disorder (PTSD), or acute stress disorder. These are not personality traits or weaknesses. They are neurological and psychological responses to trauma that require medical treatment.

Buspirone, sold under the brand name BuSpar, is one of the most commonly prescribed pharmacological treatments for generalized anxiety disorder following traumatic injury. Understanding what buspirone is, how it works, why physicians prescribe it after accidents, and how a pharmacy lien covers it for the duration of a PI case helps patients, attorneys, and treatment providers navigate care more effectively.

[!KEY] Buspirone is not a benzodiazepine and does not cause sedation, physical dependence, or cognitive impairment. This makes it the preferred anxiolytic for PI patients with prior substance use histories, patients who drive or operate machinery, and patients who require long-term anxiety management throughout the course of a litigation that may last 12–36 months.

What Is Buspirone? Mechanism of Action

Buspirone is classified as an azapirone — a chemically distinct class from benzodiazepines, SSRIs, and SNRIs. Its anxiolytic effect comes from two complementary mechanisms:

1. Partial 5-HT1A Agonism

Buspirone acts as a partial agonist at the serotonin 5-HT1A receptor. These receptors are concentrated in the raphe nuclei — the brain's primary serotonin-producing region — and in limbic areas including the hippocampus and amygdala, which govern fear responses and emotional regulation. By partially activating 5-HT1A receptors, buspirone modulates serotonergic tone in a way that reduces anxiety without the full receptor occupation that produces sedation.

The partial agonist distinction matters: full agonists can cause receptor desensitization and dependence over time. Partial agonists produce a more modest, stable effect that does not require dose escalation.

2. Dopamine D2 Partial Agonism

Buspirone also acts as a partial agonist at dopamine D2 receptors, particularly presynaptic ones. This modulates dopaminergic signaling in ways that contribute to its anxiolytic profile and may account for some of its antidepressant augmentation effects when co-prescribed with SSRIs.

What buspirone does NOT do:

• It does not bind to GABA-A receptors (the mechanism of benzodiazepines)
• It produces no clinically meaningful sedation at therapeutic doses
• It does not impair cognition or reaction time
• It carries no physical dependence potential and does not produce a withdrawal syndrome
• It has no abuse potential and is not a DEA-scheduled controlled substance

[!SOURCE] The FDA-approved prescribing information for buspirone and multiple controlled trials confirm no abuse liability, no withdrawal syndrome on discontinuation, and no cross-tolerance with benzodiazepines. See: https://pubmed.ncbi.nlm.nih.gov/2875016/

Why Buspirone Is Prescribed After a Traumatic Injury

Generalized Anxiety Disorder Following Trauma

After a significant traumatic event, the nervous system may remain in a state of heightened alert — increased vigilance, persistent worry, muscle tension, irritability, sleep disruption, and difficulty concentrating. When these symptoms persist for six months or more and cause meaningful functional impairment, the clinical diagnosis is generalized anxiety disorder.

Research consistently shows elevated GAD rates in populations that have experienced motor vehicle accidents, workplace injuries, falls, and other acute trauma. The anxiety is not limited to flashbacks or event-specific fear; it generalizes across daily functioning, relationships, and the ability to return to work or normal activity.

Buspirone is FDA-approved specifically for the management of generalized anxiety disorder and is first-line or second-line in clinical guidelines depending on the presence of comorbid depression.

When SSRIs Alone Are Insufficient

Physicians commonly co-prescribe buspirone with SSRIs (sertraline, escitalopram, fluoxetine) in PI patients who have not achieved adequate anxiety control from an SSRI alone. Buspirone augments serotonergic activity through a different receptor target, providing additive benefit without the sedation or drug interaction risk of benzodiazepines.

This co-prescription pattern is clinically significant for attorneys: it documents that the patient's anxiety was severe enough to require multi-agent treatment, which supports the severity narrative in the demand package.

Patients With Prior Substance Use History

A meaningful subset of personal injury patients have prior histories of alcohol use disorder, opioid use disorder, or other substance use. For these patients, benzodiazepines are contraindicated — they carry high cross-addiction potential and can trigger relapse. Buspirone is the appropriate anxiolytic in this population because it carries zero addiction potential.

Attorneys working with clients who have prior substance use histories can note that the treating physician's choice of buspirone reflects careful, informed prescribing — it documents the physician's awareness of the patient's vulnerability and their decision to treat appropriately.

When Hydroxyzine Is Insufficient

Hydroxyzine (Vistaril/Atarax) is often the initial anxiolytic prescribed in acute post-injury settings — it is an antihistamine with sedating properties that provide short-term relief. However, hydroxyzine's sedating effects make it poorly suited for daytime use in patients who need to function, drive, and attend medical appointments. When patients cannot tolerate hydroxyzine's sedation or when anxiety requires ongoing daily management rather than as-needed dosing, physicians transition to buspirone.

Dosing and Administration

Buspirone is typically initiated at 5 mg twice daily (BID) or three times daily (TID), then titrated upward based on response and tolerability. Therapeutic doses generally range from 15 mg to 60 mg per day, administered in divided doses.

Key clinical point: delayed onset. Unlike benzodiazepines, which produce anxiolytic effects within 30–60 minutes of a dose, buspirone requires 2–4 weeks of consistent use to produce its full anxiolytic effect. This is explained by the time needed for 5-HT1A receptor adaptation. Patients who stop taking buspirone after a few days because they "don't feel it" lose the therapeutic benefit before it has had time to establish.

Physicians routinely counsel patients on this delay. Compliance is essential, and pharmacy lien records showing continuous refills document that the patient maintained treatment as directed.

Common side effects include:

• Dizziness (usually transient in the first 1–2 weeks)
• Nausea (take with food to minimize)
• Headache
• Nervousness or restlessness early in treatment

Unlike benzodiazepines, buspirone does not cause respiratory depression, does not interact dangerously with opioids, and is safe in elderly patients.

Pharmacy Lien Coverage for Buspirone

Personal injury patients often lack health insurance or have insurance that does not cover psychiatric medications, or they fear disclosure of mental health treatment to their insurer. Under a pharmacy lien arrangement, buspirone is dispensed at no upfront cost to the patient. The pharmacy holds a lien against the eventual settlement or judgment, collecting reimbursement when the case resolves.

[!KEY] Continuous pharmacy lien records showing monthly buspirone refills create a documented medical record of ongoing anxiety treatment throughout the case duration. This timeline — beginning shortly after the accident and extending through the litigation period — is exactly the type of evidence that corroborates psychological injury claims and supports the demand package.

Because buspirone is a generic medication available at low tier on most pharmacy formularies, it is among the more straightforward medications to maintain on lien for the full duration of a PI case. Physicians who establish a patient on buspirone typically intend treatment for months to years, making the pharmacy lien model well-suited to covering it.

Documentation Value for Attorneys

Every buspirone prescription tells a story:

1. Initiation date — establishes when anxiety was first treated, which can be correlated to the accident date
2. Prescribing physician — typically a psychiatrist or treating primary care physician who can testify to the anxiety diagnosis and its causation
3. Ongoing refills — demonstrate persistence of the condition, not a brief emotional reaction
4. Co-prescribed medications — an SSRI + buspirone combination documents anxiety severity requiring multi-agent treatment

In cases involving PTSD, cognitive impairment, or psychological injury as a component of non-economic damages, the pharmacy record for buspirone is a concrete, verifiable document tying psychological diagnosis to treatment.

Related Resources

• Hydroxyzine and Anxiety Management in PI Cases
• Gabapentin vs. Pregabalin for Neuropathic Pain After an Accident
• Concussion and TBI Medication Guide
• What Is a Pharmacy Lien?
• Pain Management After a Car Accident